Clinical trials: MS (Multiple Sclerosis)
Multiple Sclerosis
A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety \& efficacy
- Trial name
- NCT02200718
- Testing
- NeuroVax, IFA Incomplete Freund's Adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Immune Response BioPharma, Inc.
Multiple Sclerosis
Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.
- Trial name
- NCT00370071
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Bayer
Multiple Sclerosis, B-Cell Deficiency
B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment
The overall aim of the study is to gain knowledge about consequences for the child´s humoral immunosystem in mothers with multiple sclerosis and due to their immunomodulating treatments.
- Conditions
- Multiple Sclerosis, B-Cell Deficiency, Offspring, Adult, Immunosuppression
- Trial name
- NCT06711354
- Testing
- Anti-CD20 Monoclonal Antibody
- Volunteers
- 111 people
- Sponsor
- Region Stockholm
Multiple Sclerosis
Silent Progression Activity Monitoring - SPAM Study
Real-World Data (RWD) exploring the natural history of MS suggested that relapses do not significantly influence the progression of irreversible disability.
- Trial name
- SPAM (NCT05650281)
- Testing
- NO INTERVENTION
- Where
- France
- Volunteers
- 2,230 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Optic Neuritis, Multiple Sclerosis
Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool
The goal of this observational study is to determine whether genetic information, together with clinical information, can be used to improve prediction of future multiple sclerosis (MS) diagnosis after a first-time episode of…
- Conditions
- Optic Neuritis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders
- Trial name
- MS Predictor (NCT07704294)
- Testing
- No Intervention: Observational Cohort
- Where
- 3 sites in United Kingdom
- Volunteers
- 180 people
- Sponsor
- King's College London
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
MS (Multiple Sclerosis)
Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study
The aim of this work is to identify different pattern of Gastrointestinal and Hepatic symptoms and its Frequency among patients with Multiple Sclerosis
- Trial name
- NCT06770959
- Volunteers
- 80 people
- Sponsor
- Assiut University
Progressive Multifocal Leukoencephalopathy
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including…
- Trial name
- NCT03399981
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 80,327 people
- Sponsor
- Biogen
Multiple Sclerosis
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
- Trial name
- CogniPlus (NCT01491100)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 17 sites in Albania, Algeria and 15 more
- Volunteers
- 1,085 people
- Sponsor
- Bayer
Multiple Sclerosis, Transverse Myelitis
Biobank For MS And Other Demyelinating Diseases
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated…
- Conditions
- Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis
- Trial name
- NCT00445367
- Where
- 10 sites in United States
- Volunteers
- 3,226 people, healthy volunteers welcome
- Sponsor
- Accelerated Cure Project for Multiple Sclerosis
Multiple Sclerosis, Relapsing Remitting
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to improve adherence is…
- Trial name
- NCT02247310
- Testing
- Interferon beta-1b (Betaferon®, BAY 86-5046), BETACONNECT
- Where
- 11 sites in Austria, Belgium and 9 more
- Volunteers
- 498 people
- Sponsor
- Bayer
Multiple Sclerosis
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for MS
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of multiple sclerosis
- Trial name
- NCT05003388
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- Where
- 2 sites in United States, Greece
- Volunteers
- 15 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Multiple Sclerosis
T-Cell Vaccination in Multiple Sclerosis (MS)
The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.
- Trial name
- NCT00220428
- Testing
- T-Cell Vaccination
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Sheba Medical Center
Multiple Sclerosis
Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)
Multiple sclerosis (abbreviated MS) is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination.
- Trial name
- NCT00674934
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength)
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- GAAD Medical Research Institute Inc.
Multiple Sclerosis
Oral Cladribine B-cell Study
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells and Tregs
- Trial name
- NCT06415864
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
- Trial name
- NCT01892722
- Testing
- Interferon beta-1a, Fingolimod
- Where
- 73 sites in United States, Australia and 23 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Betaferon Use in Children and Adolescents With Multiple Sclerosis
The objective of this study is to determine efficacy, safety and tolerability of interferon beta-1b for multiple sclerosis (MS) in children and adolescents
- Trial name
- NCT03577977
- Testing
- Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- Bayer
Multiple Sclerosis
Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is mainly known as a disease of young to middle adulthood but approximately 5% of all MS cases worldwide involve children that are younger than 16 years.
- Trial name
- NCT00963833
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 6 sites in Austria, Belgium and 4 more
- Volunteers
- 68 people
- Sponsor
- Bayer
M-health, Multiple Sclerosis
haMSter: a Novel Smartphone Communication Tool for People With MS
haMSter is a smartphone app that tracks validated patient reported outcome measures (PROMs) in people multiple sclerosis (MS). In this study, 50 patients with MS will receive this app for 6 months and be asked to fill out the PRO…
- Trial name
- NCT04555863
- Testing
- haMSter smartphone app
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Multiple Sclerosis
TELEMS: Feasibility of Remote Patient Visits in MS
This trials randomizes patients with multiple sclerosis (MS, pwMS) to a remote visit (via phone or videochat) or a regular outpatient visit. Outcomes include satisfaction on the patients' and doctor's side.
- Trial name
- TELEMSRCT (NCT04838990)
- Testing
- EDSS, Discussion of symptoms, Patient reported outcome (MSIS)
- Where
- Austria
- Volunteers
- 45 people
- Sponsor
- Medical University of Vienna